Evidence map›Paper›PMID 36945491›Full record

ArticlebioRxiv : the preprint server for biology2023

signifinder enables the identification of tumor cell states and cancer expression signatures in bulk, single-cell and spatial transcriptomic data.

Stefania Pirrotta, Laura Masatti, Anna Corrà, Fabiola Pedrini, Giovanni Esposito, Paolo Martini, Davide Risso, Chiara Romualdi, Enrica Calura

Full text readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Stefania PirrottaDepartment of Biology, University of Padua, Padua, Italy.
Laura MasattiDepartment of Biology, University of Padua, Padua, Italy.
Anna CorràDepartment of Biology, University of Padua, Padua, Italy.
Fabiola PedriniDepartment of Biology, University of Padua, Padua, Italy.
Giovanni EspositoImmunology and Molecular Oncology Diagnostic Unit of The Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Paolo MartiniDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Davide RissoDepartment of Statistical Sciences, University of Padua, Italy.
Chiara RomualdiDepartment of Biology, University of Padua, Padua, Italy.
Enrica CaluraDepartment of Biology, University of Padua, Padua, Italy.

Funding

Cancer Genomics:Integrative and Scalable Solutions in R / BioconductorU24CA180996 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MORGAN, MARTIN T, WALDRON, LEVI · 2014 to 2023
$6.9M
NCI NIH HHS U24 CA180996
6 · The paper itself

Abstract

Over the last decade, many studies and some clinical trials have proposed gene expression signatures as a valuable tool for understanding cancer mechanisms, defining subtypes, monitoring patient prognosis, and therapy efficacy. However, technical and biological concerns about reproducibility have been raised. Technical reproducibility is a major concern: we currently lack a computational implementation of the proposed signatures, which would provide detailed signature definition and assure reproducibility, dissemination, and usability of the classifier. Another concern regards intratumor heterogeneity, which has never been addressed when studying these types of biomarkers using bulk transcriptomics. With the aim of providing a tool able to improve the reproducibility and usability of gene expression signatures, we propose

Identifiers

PMID36945491
PMCPMC10028855

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read11
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.